Glenmark Pharmaceuticals to Directly Commercialize RYALTRIS in U.S.
Filing Summary
Glenmark Pharmaceuticals Ltd has announced a strategic shift to manage the direct commercialization and distribution of its product, RYALTRIS, in the United States starting April 1, 2026. RYALTRIS, a nasal spray approved by the U.S. FDA for treating Seasonal Allergic Rhinitis, combines olopatadine hydrochloride and mometasone furoate. This move marks Glenmark’s expansion in the U.S. market, enhancing its presence and aligning with healthcare providers. RYALTRIS is already available in 55 countries, including key markets like the European Union and China.
Glenmark Pharmaceuticals Ltd has announced that its subsidiary, Glenmark Pharmaceuticals Inc., USA, will undertake the direct commercialization and distribution of RYALTRIS in the United States, effective April 1, 2026. This strategic shift involves managing the end-to-end processes for RYALTRIS, a nasal spray combining olopatadine hydrochloride and mometasone furoate, which is approved by the U.S. FDA for treating symptoms of Seasonal Allergic Rhinitis in patients aged 12 and older.
The financial terms related to this strategic shift were not disclosed in the filing. However, the move signifies Glenmark’s commitment to establishing a direct commercial presence in the U.S. market. By taking control of the commercialization and distribution processes, Glenmark aims to enhance its operational direction and market engagement, focusing on brand strategy, market access, and customer engagement for RYALTRIS.
The scope of this initiative includes the management of all aspects of RYALTRIS in the U.S., from brand strategy to market access and customer engagement. The product is a fixed-dose combination nasal spray, supplied as a 240-metered spray nasal suspension, designed to offer a convenient treatment option by combining two established therapies. This aligns with evolving patient and physician preferences for treating Seasonal Allergic Rhinitis, a condition affecting millions across the United States.
RYALTRIS was initially launched in the U.S. market in 2022 and has since expanded its presence to 55 countries, including key markets such as the European Union, United Kingdom, Australia, South Korea, Russia, and China. The product’s approval in these regions underscores its global reach and the strategic importance of the U.S. market in Glenmark’s broader business objectives.
The implementation of this strategic shift is set to begin on April 1, 2026. Glenmark will lead all aspects of the commercialization process, ensuring closer alignment with healthcare providers and greater responsiveness to market needs. This development is part of Glenmark’s broader effort to strengthen its innovative business operations in the U.S. and build a more direct, sustainable commercial presence over time.
Glenmark Pharmaceuticals Ltd is a global, research-led pharmaceutical company focused on innovation and accessibility. The company is engaged in developing transformative therapies and expanding access to high-quality, affordable medicines worldwide. With a diversified portfolio across branded, innovative, generics, and consumer health products, Glenmark emphasizes respiratory, dermatology, and oncology sectors. The company operates 11 manufacturing facilities and six R&D centers across four continents, maintaining a commercial footprint in over 80 countries.